Group 1: Yingjie Electric - In 2024, Yingjie Electric's revenue is projected to be 1.78 billion yuan, a year-on-year increase of 0.59%, while net profit is expected to decline by 25.19% due to delays in revenue recognition in the photovoltaic industry, inventory write-downs, and increased expenses [1] - The company's cash flow from operating activities increased significantly to 601.77 million yuan, up by 46.20 million yuan year-on-year [1] - New orders decreased by approximately 40%, but the backlog remains over 2.7 billion yuan, with expectations for overseas photovoltaic orders to contribute to revenue recognition by 2025 [1] Group 2: Dingyang Technology - Dingyang Technology has established a comprehensive sales system in the global market, exporting to over 80 countries and regions [2] - The company has launched 10 new products in 2024 and 6 new products in 2025, focusing on high-end electronic testing and measurement instruments [2] - Dingyang aims to enhance its international brand influence and market share through a high-end development strategy and improved marketing channels [2] Group 3: Aibo Medical - Aibo Medical achieved total revenue of 1.41 billion yuan in 2024, a year-on-year increase of 48.24%, with net profit rising by 27.77% [3] - The company is experiencing significant growth in its Dragon Crystal® PR product line, although initial production quality and costs are challenges [3] - Aibo Medical's artificial lens business is expanding, with a notable increase in market share and a focus on high-end products to counteract price drops due to industry policies [3] Group 4: Libang Instruments - In Q1 2025, Libang Instruments reported revenue of 420 million yuan, a decline of 5%, with domestic sales down by 20% but international sales up by 7% [4] - The company is optimistic about domestic sales recovery due to improved market conditions and is leveraging AI technology in ultrasound imaging and smart healthcare [4] - Libang's gross margin is expected to rise to 57.92% in 2024, driven by increased sales of high-margin products [4]

Core Viewpoint - Recent research by Yixin An Asset Management on Aibo Medical indicates strong revenue growth and challenges in production quality, with a focus on expanding market share in the ophthalmic medical materials sector [1] Company Summary - Aibo Medical is projected to achieve total revenue of 1.41 billion yuan in 2024, representing a year-on-year increase of 48.24%, with a net profit of 388 million yuan, up 27.77% [1] - In Q1 2025, revenue is expected to grow by 15.07%, although net profit is anticipated to decline [1] - The Dragon Crystal® PR product is performing well in promotion, with positive feedback from doctors, but initial production quality is low and costs are high, leading to expectations of significant sales growth in Q2 [1] - The All-View® series and Dragon Crystal® products together account for over one-third of the revenue from the artificial lens business, with the All-View® series contributing approximately 25% [1] - The company has expanded its surgical treatment business to over 3,500 hospitals, indicating a significant increase in market share [1] - Despite a panic-driven price drop in the industry due to centralized procurement policies, the proportion of high-end products has increased, leading to a significant rebound in average sales prices [1] - Aibo Medical has optimized its production line layout and personnel configuration to reduce the comprehensive production costs of artificial lenses [1] - The volume of artificial lenses shipped in 2024 is expected to grow by over 40% year-on-year, with implant volume increasing by over 30% [1] - The company is facing challenges with non-spherical trifocal astigmatism correction artificial lenses in the centralized procurement process, while the non-spherical extended depth of focus (EDoF) lenses are expected to participate [1] - Aibo Medical has established a cross-disciplinary process special team to focus on key areas such as materials and molds [1] - The average factory price of orthokeratology lenses has increased, while the growth of defocus frame lenses has slowed in Q1 of this year [1] - The company has a long-term focus on the biomedical materials field, extending its business from ophthalmology to medical repair, orthopedics, and sports medicine [1] - Aibo Medical's closed-loop system of independent research and production effectively mitigates risks from external supply chain disruptions or increased tariffs [1] - The surgical treatment business is expected to continue growing, with the myopia prevention business enhancing market share through high-end products, and the contact lens business improving gross margins through technological optimization [1]